Amarantus Bioscience Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0007
- Today's High:
- $0.0008
- Open Price:
- $0.0008
- 52W Low:
- $0.0011
- 52W High:
- $0.01
- Prev. Close:
- $0.0007
- Volume:
- 100001
Company Statistics
- Market Cap.:
- $3.22 million
- Book Value:
- -0.125
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Amarantus Bioscience Holdings Inc had its IPO on under the ticker symbol AMBS.
The company operates in the Healthcare sector and Biotechnology industry. Amarantus Bioscience Holdings Inc has a staff strength of 0 employees.
Stock update
Shares of Amarantus Bioscience Holdings Inc opened at $0 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0, and closed at $0.
This is a 0% increase from the previous day's closing price.
A total volume of 100,001 shares were traded at the close of the day’s session.
In the last one week, shares of Amarantus Bioscience Holdings Inc have slipped by -22.22%.
Amarantus Bioscience Holdings Inc's Key Ratios
Amarantus Bioscience Holdings Inc has a market cap of $3.22 million, indicating a price to book ratio of 53.1851 and a price to sales ratio of 0.
In the last 12-months Amarantus Bioscience Holdings Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Amarantus Bioscience Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Amarantus Bioscience Holdings Inc’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Amarantus Bioscience Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Amarantus Bioscience Holdings Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.08 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amarantus Bioscience Holdings Inc’s profitability.
Amarantus Bioscience Holdings Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.3969. Its price to sales ratio in the trailing 12-months stood at 0.
Amarantus Bioscience Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.54 million
- Total Liabilities
- $35.54 million
- Operating Cash Flow
- $-1013092.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Amarantus Bioscience Holdings Inc ended 2025 with $5.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.54 million while shareholder equity stood at $-31604750.00.
Amarantus Bioscience Holdings Inc ended 2025 with $0 in deferred long-term liabilities, $35.54 million in other current liabilities, 250808.00 in common stock, $-116972030.00 in retained earnings and $0 in goodwill. Its cash balance stood at $178.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Amarantus Bioscience Holdings Inc’s total current assets stands at $782666.00 while long-term investments were $4.75 million and short-term investments were $0. Its net receivables were $34213.00 compared to accounts payable of $14.82 million and inventory worth $0.
In 2025, Amarantus Bioscience Holdings Inc's operating cash flow was $-1013092.00 while its capital expenditure stood at $0.
Comparatively, Amarantus Bioscience Holdings Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $0
- 52-Week High
- $0.01
- 52-Week Low
- $0.0011
- Analyst Target Price
- $
Amarantus Bioscience Holdings Inc stock is currently trading at $0 per share. It touched a 52-week high of $0.01 and a 52-week low of $0.01. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Amarantus Bioscience Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.